LIVN:NASDAQLivaNova PLC Analysis

LivaNova is trading at $72.36, just below its 20‑day SMA of $72.74 but comfortably above the 50‑day ($67.23) and 200‑day ($61.55) averages, indicating a short‑term pull‑back within a longer‑term uptrend. The RSI of 54.5 suggests neutral momentum, while the MACD histogram is negative, hinting at near‑term bearish pressure, yet the broader trend remains bullish with support at $69.17 and resistance at $75.82. Valuation metrics are mixed: a trailing P/E of 36.9 is well above the industry average of 27.9, but the DCF fair value of $89.9 implies roughly 11% upside, and the forward P/E of 15.6 looks reasonable. Fundamentally, the company posted a 14% revenue increase to $362 M, turned a net loss into a $22 M profit, and lifted EPS guidance to $4.20‑$4.30, supported by FDA pre‑market approval for the aura6000 OSA system and an upgraded analyst consensus to “Buy”. Cash on hand of $540 M versus $343 M debt gives a low leverage profile, while operating margins of 14% and a gross margin near 68% underscore strong profitability. The market sentiment is bullish, reflected in an “Extreme Greed” fear‑greed index and a consensus target price around $80.5, which aligns with the DCF upside potential.